Evidence map›Paper›PMID 29272550›Full record

ArticleBritish journal of pharmacology2018

Different contributions of chemokine N-terminal features attest to a different ligand binding mode and a bias towards activation of ACKR3/CXCR7 compared with CXCR4 and CXCR3.

Martyna Szpakowska, Amanda M Nevins, Max Meyrath, David Rhainds, Thomas D'huys, François Guité-Vinet, Nadine Dupuis, Pierre-Arnaud Gauthier, Manuel Counson, Andrew Kleist and 6 more

Open access · greenAbstract readComparative Study
In one paragraph

Article in British journal of pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
2.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 66 citations in OpenAlex.

  1. Article
  2. Article
  3. Atypical GPCR Activation Resolved by Nanobody Engineering.bioRxiv : the preprint server for biology · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. The present and future of immunocytokines for cancer treatment.Cellular and molecular life sciences : CMLS · 2022
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 4 countries.

Martyna SzpakowskaDepartment of Infection and Immunity, Immuno-Pharmacology and Interactomics, Luxembourg Institute of Health (LIH), Esch-sur-Alzette, Luxembourg.
Amanda M NevinsDepartment of Biochemistry, Medical College of Wisconsin, Milwaukee, WI, USA.
Max MeyrathDepartment of Infection and Immunity, Immuno-Pharmacology and Interactomics, Luxembourg Institute of Health (LIH), Esch-sur-Alzette, Luxembourg.
David RhaindsResearch Centre, Saint-Justine Hospital, University of Montreal, Montréal, QC, Canada.
Thomas D'huysLaboratory of Virology and Chemotherapy, Rega Institute for Medical Research, University of Leuven, Leuven, Belgium.
François Guité-VinetResearch Centre, Saint-Justine Hospital, University of Montreal, Montréal, QC, Canada.
Nadine DupuisLaboratory of Molecular Pharmacology, GIGA-Molecular Biology of Diseases, University of Liège, Liège, Belgium.
Pierre-Arnaud GauthierDepartment of Infection and Immunity, Immuno-Pharmacology and Interactomics, Luxembourg Institute of Health (LIH), Esch-sur-Alzette, Luxembourg.
Manuel CounsonDepartment of Infection and Immunity, Immuno-Pharmacology and Interactomics, Luxembourg Institute of Health (LIH), Esch-sur-Alzette, Luxembourg.
Andrew KleistDepartment of Biochemistry, Medical College of Wisconsin, Milwaukee, WI, USA.
Geneviève St-OngeResearch Centre, Saint-Justine Hospital, University of Montreal, Montréal, QC, Canada.
Julien HansonLaboratory of Molecular Pharmacology, GIGA-Molecular Biology of Diseases, University of Liège, Liège, Belgium.
Dominique ScholsLaboratory of Virology and Chemotherapy, Rega Institute for Medical Research, University of Leuven, Leuven, Belgium.
Brian F VolkmanDepartment of Biochemistry, Medical College of Wisconsin, Milwaukee, WI, USA.
Nikolaus HevekerResearch Centre, Saint-Justine Hospital, University of Montreal, Montréal, QC, Canada.
Andy ChevignéDepartment of Infection and Immunity, Immuno-Pharmacology and Interactomics, Luxembourg Institute of Health (LIH), Esch-sur-Alzette, Luxembourg.ORCID 0000-0003-4768-6743
Luxembourg Institute of Health · LUCentre Hospitalier Universitaire Sainte-Justine · CAMedical College of Wisconsin · USRega Institute for Medical Research · BEUniversity of Liège · BE

Funding

Medical Scientist Training ProgramT32GM080202 · NIGMS · MEDICAL COLLEGE OF WISCONSIN · PI BARBIERI, JOSEPH T, SALZMAN, NITA H · 2010 to 2024
$5.7M
Structural Basis for Chemokine FunctionR01AI058072 · NIAID · MEDICAL COLLEGE OF WISCONSIN · PI VOLKMAN, BRIAN F · 2004 to 2019
$4.1M
Structural Basis for Chemokine FunctionR37AI058072 · NIAID · MEDICAL COLLEGE OF WISCONSIN · PI Brian F Volkman · 2020 to 2026
$2.8M
Structural basis of chemokine receptor signaling in tumor progressionF30CA196040 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI KLEIST, ANDREW B · 2016 to 2020
$233k
CIHR MOP123421NCI NIH HHS F30 CA196040NIAID NIH HHS R01 AI058072NIAID NIH HHS R37 AI058072NIGMS NIH HHS T32 GM080202
6 · The paper itself

Abstract

background and purposeChemokines and their receptors form an intricate interaction and signalling network that plays critical roles in various physiological and pathological cellular processes. The high promiscuity and apparent redundancy of this network makes probing individual chemokine/receptor interactions and functional effects, as well as targeting individual receptor axes for therapeutic applications, challenging. Despite poor sequence identity, the N-terminal regions of chemokines, which play a key role in their activity and selectivity, contain several conserved features. Thus far little is known regarding the molecular basis of their interactions with typical and atypical chemokine receptors or the conservation of their contributions across chemokine-receptor pairs. EXPERIMENTAL APPROACH: We used a broad panel of chemokine variants and modified peptides derived from the N-terminal region of chemokines CXCL12, CXCL11 and vCCL2, to compare the contributions of various features to binding and activation of their shared receptors, the two typical, canonical G protein-signalling receptors, CXCR4 and CXCR3, as well as the atypical scavenger receptor CXCR7/ACKR3, which shows exclusively arrestin-dependent activity. KEY

resultsWe provide molecular insights into the plasticity of the ligand-binding pockets of these receptors, their chemokine binding modes and their activation mechanisms. Although the chemokine N-terminal region is a critical determinant, neither the most proximal residues nor the N-loop are essential for binding and activation of ACKR3, as distinct from binding and activation of CXCR4 and CXCR3. CONCLUSION AND IMPLICATIONS: These results suggest a different interaction mechanism between this atypical receptor and its ligands and illustrate its strong propensity to activation.

Indexed as

Binding SitesProtein BindingAnimalsArrestinCells, CulturedChemokine CXCL11Chemokine CXCL12HumansLigandsPeptidesRadioligand AssayReceptors, CXCRReceptors, CXCR3Receptors, CXCR4ACKR3 protein, humanArrestinChemokine CXCL11Chemokine CXCL12CXCL11 protein, humanCXCL12 protein, humanCXCR3 protein, humanCXCR4 protein, humanLigandsPeptidesReceptors, CXCRReceptors, CXCR3Receptors, CXCR4

Identifiers

PMID29272550
PMCPMC5900987
OpenAlexW2804140086

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.